Key Takeaway: Pfizer presented positive results from a Phase 2 study of tilrekimig for atopic dermatitis. The study achieved its primary endpoint, showing a significant increase in skin clearance among participants. This was measured by the Eczema Area and Severity Index at Week 16, indicating promising efficacy for the treatment.
Market Sentiment Analysis
POSITIVE FACTORS
Tilrekimig showed significant skin clearance in patients.
The study met its primary endpoint successfully.
Results indicate a strong efficacy compared to placebo.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+6%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
ibuzatrelvir
Phase 3 · COVID-19 SARS-CoV-2 Infection
Full Press Release Details
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo. The findings were shared today in
Frequently Asked Questions
What is tilrekimig used for?
Tilrekimig is being investigated for treating moderate-to-severe atopic dermatitis.
What were the results of the Phase 2 study?
The study showed a significant increase in skin clearance among participants.
What does EASI-75 mean?
EASI-75 indicates a 75% reduction in the Eczema Area and Severity Index.
When were the results presented?
The results were presented today by Pfizer in New York.